Immunoregulation with methisoprinol in Sjögren's syndrome.
In this work, we studied the therapeutic clinical efficacy and the immunoregulating effect of methisoprinol in 4 cases of primary SS and one case of secondary SS. After 12 weeks of treatment, no significant clinical improvement was detected in the glandular histology, in Schirmer's test and sialography. On the other hand, we have observed the following alterations: immunological changes characterized by an increase in the total population of T-lymphocytes (OKT3), a normalization and thereby a diminution in IgM, an increase in T-helper subpopulation (OKT4) in four cases and in T-suppressor subpopulation in one case. A noticeable fact was the best immunological response of the patient showing a negative histology, a functional alteration of the parotid and a short evolution of the syndrome. These findings support the hypothesis that methisoprinol can be an efficient coadjuvant in the treatment of primary Sjögren's syndrome in early stages when there is only functional alteration but no glandular atrophy.
A
A
Sánchez Palacios
A
A
Quintero
A
A
Clavero Garín
A
A
Verrier Hernández
A
A
Esposo Ferrero
A
A
Sánchez Ruiz
D
D
Iglesias
R
R
Aparicio Duque
D000328:Adult; D000368:Aged; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007075:Immunoglobulin M / Q000032:analysis; D007288:Inosine / Q000031:analogs & derivatives*; D007542:Inosine Pranobex / Q000627:therapeutic use*; D008875:Middle Aged; D010306:Parotid Gland / Q000000981:diagnostic imaging / Q000473:pathology; D011859:Radiography; D012859:Sjogren's Syndrome / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D013601:T-Lymphocytes / Q000145:classification / Q000276:immunology
D007075:Immunoglobulin M; D007288:Inosine; D007542:Inosine Pranobex